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Available online 5 October 2016Cholesterol crystalline domains characterize atherosclerotic membranes, altering vascular signaling and function.
Omega-3 fatty acids reduce membrane lipid peroxidation and subsequent cholesterol domain formation. We
evaluated non-peroxidation-mediated effects of eicosapentaenoic acid (EPA), other TG-lowering agents,
docosahexaenoic acid (DHA), and other long-chain fatty acids onmembrane ﬂuidity, bilayer width, and cholesterol
domain formation in model membranes. In membranes prepared at 1.5:1 cholesterol-to-phospholipid (C/P) mole
ratio (creating pre-existing domains), EPA, glycyrrhizin, arachidonic acid, and alpha linolenic acid promoted the
greatest reductions in cholesterol domains (by 65.5%, 54.9%, 46.8%, and 45.2%, respectively) compared to controls;
other treatments had modest effects. EPA effects on cholesterol domain formation were dose-dependent. In mem-
branes with 1:1 C/P (predisposing domain formation), DHA, but not EPA, dose-dependently increased membrane
ﬂuidity. DHA also induced cholesterol domain formationwithout affecting temperature-induced changes in–bilayer
unit cell periodicity relative to controls (d-space; 57 Å–55 Å over 15–30 °C). Together, these data suggest simulta-
neous formation of distinct cholesterol-rich ordered domains and cholesterol-poor disordered domains in the pres-
ence of DHA. By contrast, EPA had no effect on cholesterol domain formation and produced larger d-space values
relative to controls (60Å–57Å; p b 0.05) over the same temperature range, suggesting amore uniformmaintenance
of lipid dynamics despite the presence of cholesterol. These data indicate that EPA and DHA had different effects on
membrane bilayer width, membrane ﬂuidity, and cholesterol crystalline domain formation; suggesting omega-3
fatty acids with differing chain length or unsaturation may differentially inﬂuence membrane lipid dynamics and
structural organization as a result of distinct phospholipid/sterol interactions.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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B.V. This is an open access article uintracellular accumulation of cholesterol promotes increased deposition
of free cholesterol in the plasmamembrane, resulting in the formation of
membrane-restricted cholesterol crystalline domains [2,3]. Such changes
in membrane lipid structural organization are associated with an in-
crease in membrane permeability, generation of reactive oxygen species
(ROS), and lipid peroxidation, all of which further degrade membrane
structure and interferewith its proper function [4,5]. The continued con-
centration of cholesterol in the plasma membrane eventually promotes
the formation of extracellular cholesterol crystals—jagged, microscopic
shards that can expand rapidly and puncture the protective ﬁbrous cap
of an atherosclerotic lesion [2,6,7]. These crystals are also believed to trig-
ger inﬂammatory pathways that result in both necrotic and apoptotic
forms of cell death [8].
Unesteriﬁed or free cholesterol is a key component of caveolae that
serve as important signaling domains on the surface of normal cellular
membranes. Caveolin, the principal structural protein associated withnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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various receptor tyrosine kinases, G protein-coupled receptors,
glycophosphatidylinositol (GPI)-linked proteins, ion channels, and en-
dothelial nitric oxide synthase (eNOS) [5,9]. Through these proteins, ca-
veolae mediate endothelial function, smooth muscle cell migration,
cytokine expression, energy metabolism, and innate immunity, includ-
ing the recruitment and activation of inﬂammatory cells. Cholesterol is a
critical structural component of the caveolar membrane and must be
maintained within narrow homeostatic limits in order for caveolae to
perform these critical activities. Excessive accumulation of cholesterol
and the subsequent formation of cholesterol domainsmay lead to endo-
thelial dysfunction, localized inﬂammation, and potentiation of the ath-
erogenic process [5]. Even minor structural disruptions to cellular
membranes and caveolae, through deposition of excess cholesterol or
oxidative modiﬁcation, have been shown to adversely affect normal
cell function [9,10].
Treatment of hypercholesterolemia with statins results in signiﬁcant
reductions in circulating cholesterol and cardiovascular risk; however, in-
dividuals with well-controlled low-density lipoprotein cholesterol (LDL-
C) levels, but persistent hypertriglyceridemia (HTG) and elevated levels
of other circulating lipoproteins, remain at increased risk for cardiovascu-
lar disease [11–16]. Medical management of HTG with marine-derived,
long-chain, polyunsaturated omega-3 fatty acids (O3FAs) has been
shown to signiﬁcantly reduce plasma triglycerides (TG) but O3FA treat-
ment, as shown in a number of well-controlled clinical trials, has not re-
sulted in consistent reduction of cardiovascular risk [17–30]. One
potential confounder in assessing the clinical utility of O3FAs in reducing
cardiovascular risk is the heterogeneity of O3FA formulations and doses
used in these various studies. Some O3FA formulations contained both
eicosapentaenoic acid (EPA; 20:5, n-3) and docosahexaenoic acid
(DHA; 22:6, n-3), and at different ratios, while others contained only
EPA. It is generally assumed that EPA and DHA behave in similar ways;
however, increasing evidence suggests otherwise. Indeed, recent data in-
dicate that EPA and DHA segregate into separate domains in cell mem-
branes, which may differentially affect membrane structure and
function [31–33].
O3FAs play important roles in a variety of cellular processes and
have been shown to reduce circulating triglycerides, cholesterol-
containing remnant lipoproteins, oxidized LDL-C (oxLDL-C), monocyte
and macrophage adhesion, and foam cell formation. Data also suggest
that EPA has other direct beneﬁts, such as improving endothelial func-
tion, stabilizing plaque to prevent rupture and thrombus formation, re-
ducing plaque volume, and reducing inﬂammatory markers [4,34–42].
These beneﬁts may be due in part to the unique physicochemical prop-
erties of EPA, which allow it to interact directly with plaque and cellular
components. O3FAs are highly lipophilic and small enough to interca-
late directly into lipoprotein particles and lipid bilayers where they
play important roles in themaintenance of endothelial function, inﬂam-
mation, activation of inﬂammatory cells, and platelet activation
[43–46].
We recently showed that EPA, but not vitamin E, fenoﬁbrate, niacin, or
gemﬁbrozil, inhibits the oxidation of apolipoprotein B (ApoB)-containing
lipid particles, including LDL, small dense low-density lipoprotein
(sdLDL), and very low-density lipoprotein (VLDL), obtained from healthy
subjects [47,48]. In addition, treatment with EPA resulted in a dose-
dependent reduction in lipid peroxidation and cholesterol domain forma-
tion in model membranes exposed to glucose-induced oxidative stress.
DHA also inhibited lipoprotein oxidation, but its effects were limited to
a shorter time period. These data suggest that differences in hydrocarbon
chain length or the number of double bondsmay differentially effect how
EPA and DHA interact with the lipoprotein, including their precise orien-
tation and location in the particle lipid layer, leading to differences in their
ability to inhibit lipid oxidation [48]. In this study,weexpandourprevious
work by evaluating the direct, non-peroxidation-mediated effects of EPA,
other TG-lowering agents, and DHA on membrane ﬂuidity and mem-
brane structural properties, including cholesterol crystalline domainformation and changes in membrane width in cholesterol-enriched
model membranes. These data will provide additional insights as to the
direct effects of EPA and DHA on membrane structure and function.
2. Materials and methods
2.1. Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) andmo-
nomeric cholesterol were purchased from Avanti Polar Lipids (Alabas-
ter, AL, USA) and solubilized in HPLC-grade chloroform at 25 and 10
mg/mL, respectively. EPA, DHA, docosapentaenoic acid (DPA; 22:5, n-
3), α-linolenic acid (ALA; 18:3, n-3), arachidonic acid (AA; 20:4, n-6),
and glycyrrhizin were purchased from Sigma-Aldrich (Saint Louis,
MO, USA) and solubilized in ethanol to 1.0 mM under nitrogen atmo-
sphere. Glycyrrhizin is a glycosylated sterol that has been shown to re-
duce the domain formation inmodelmembranes [49] andwas included
in this study as a positive control. Fenoﬁbrate, gemﬁbrozil, and nicotinic
acid (niacin) were purchased from Toronto Research Chemicals (North
York, Ontario, Canada) and solubilized in ethanol at 1.0 mM. DPH was
obtained from Molecular Probes/Invitrogen (Eugene, OR). All test
compounds were further diluted in ethanol or aqueous buffer as
needed.
2.2. Preparation of multilamellar lipid vesicles
Multilamellar vesicles (MLVs) were prepared as binary mixtures of
POPC (1.0 mg total phospholipid per sample) and cholesterol at C/P
mole ratios of 1.1:1 and 1.5:1. Cholesterol has been observed, in a num-
ber of membrane lipid systems, to undergo lateral phase separation at
C/Pmole ratios greater than 1:1 [3,50,51]. We have observed similar ef-
fects in POPC prepared at C/P mole ratios ranging from 1:1 to 2:1.
Component lipids (in chloroform) were transferred to 13 × 100mm
borosilicate culture tubes and combined with vehicle (ethanol) or an
equal volume of EPA, DHA, DPA, ALA, AA, fenoﬁbrate, gemﬁbrozil, or ni-
acin stock solutions, each adjusted to achieve desired treatment concen-
trations. Agents were tested at either 1:30 or 1:19 total treatment-to-
phospholipid (T/P) mole ratios (3.2 and 5 mol%, respectively). EPA
and DHA were also tested in combination after adjusting each to 50%
of these target concentrations.
Samples were shell-dried under nitrogen gas and placed under vac-
uum for 3 h to remove residual solvent. After desiccation, each sample
was resuspended in saline buffer (0.5 mM HEPES, 154 mM NaCl,
pH 7.3,warmed to room temperature) to yield a ﬁnal phospholipid con-
centration of 2.5 mg/mL. Lipid suspensions were then vortexed for
3 min at ambient temperature to form MLVs [52].
2.3. X-ray diffraction analysis
Membrane samples were oriented for x-ray diffraction analysis as
previously described [53]. Brieﬂy, a 100 μL aliquot (containing 250 μg
of phospholipid) was aspirated from each MLV sample and transferred
to a Lucite® sedimentation cell ﬁtted with an aluminum foil substrate
upon which a given membrane sample could be collected upon centri-
fugation. Samples were then loaded into a Sorvall AH-629 swinging
bucket ultracentrifuge rotor (Dupont Corp., Wilmington, DE, USA) and
centrifuged at 35,000g, 5 °C, for 90 min.
Following membrane orientation, sample supernatants were aspi-
rated and aluminum foil substrates, each supporting a singlemembrane
pellet, were removed from the sedimentation cells and mounted onto
custom-designed, curved glass slides. The membrane samples were
then placed in hermetically sealed containers in which temperature
and relative humidity were controlled prior to and during x-ray diffrac-
tion analysis. Data reported in this study were collected at various tem-
peratures (15 °C, 20 °C, and 30 °C) and 74% relative humidity.
Experimental humidity conditions were established by exposing
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(K2C4H4O6 ∙ 1/2 H2O). Samples were incubated at test conditions for at
least 1 h prior to experimental analysis.
Each oriented membrane sample was aligned at grazing incidence
with respect to a CuKα x-ray beam (Kα1 and Kα2 unresolved; λ =
1.54 Å) produced by a Rigaku Rotaﬂex RU-200, high brilliancemicrofocus
generator (Rigaku-MSC, TheWoodlands, TX, USA) and collimated using a
single Franks' mirror as previously described [54]. Diffraction data were
collected on a one-dimensional, position-sensitive electronic detector
(Hecus X-ray Systems, Graz, Austria) spaced 150 mm from the sample
site. Detector calibrationwas performedby themanufacturer and veriﬁed
using crystalline cholesterol monohydrate. Each sample was analyzed at
least 12 h after membrane pellet preparation andwas retested up to sev-
eral days after initial analysis.
This technique allows for precise measurement of the unit cell peri-
odicity, or d-space, of the membrane lipid bilayer, which is the distance
from the center of one lipid bilayer to the next, including surface hydra-
tion. The d-space for any given membrane multibilayer is calculated
from Bragg's Law,
hλ ¼ 2dsinθ ð1Þ
where h is the diffraction order, λ is the wavelength of the x-ray radia-
tion (1.54 Å), d is the membrane lipid bilayer unit cell periodicity, and θ
is the Bragg angle (equal to one-half the angle between the incident
beam and scattered beam).
The presence of cholesterol domains in a givenmembrane sample re-
sults in the production of distinct Bragg (diffraction) peaks having singu-
lar periodicity values of 34 and 17 Å (ﬁrst- and second-order cholesterol
domain peaks, respectively) [55–57]. Under the speciﬁc temperature and
relative humidity conditions established for these experiments, the
second-order (17 Å) cholesterol domain peak is well-delineated from
other, neighboring cholesterol and phospholipid diffraction peaks mak-
ing it particularly useful for quantitating relative cholesterol domain
peak intensity. Routines written in Origin 8.6 (OriginLab Corporation,
Northampton, MA, USA) were used to quantitate second-order choles-
terol domain peak intensity,whichwas normalized to the sumarea asso-
ciated with all phospholipid diffraction peaks in a given diffraction
pattern.
2.4. Preparation of large unilamellar vesicles
Fluorescent anisotropy experiments were conducted using large
unilamellar vesicles (LUVs) of 100 nm diameter, composed of either
POPC alone or POPC/cholesterol binary mixtures, each containing in-
creasing concentrations of EPA or DHA (0–10 mol%) and treated with
the ﬂuorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH), at 1 mol%.
DPH is a cylindrically-shaped molecule with absorption and ﬂuores-
cence emission transition dipoles aligned approximately parallel to its
long axis. Consequently, the ﬂuorescence polarization of DPH is high
in the absence of rotational motion and very sensitive to reorientation
along its long axis resulting from interactions with surrounding lipids.
These properties have led to its extensive use in membrane ﬂuidity
measurements.
In this study, each sample was prepared by combining 320 nmol
total lipid (POPC alone or POPC plus 50 mol% cholesterol), 3.2 nmol
DPH, and dose-dependent aliquots of vehicle (ethanol), EPA, or DHA.
Components were mixed well, dried under a stream of nitrogen at
35 °C, and then placed under high vacuum for at least 3 h to remove re-
sidual solvent. Each samplewas then resuspended in 1mLaqueous buff-
er (10 mM NaH2PO4, 150 mM NaCl, pH 7.4) and vortexed for 3 min to
uniformly disperse the lipids and form homogeneous MLVs. The buffer
was maintained at a temperature well above the phospholipid phase
transition temperature during this and all subsequent lipid vesicle prep-
aration steps.LUVs of 100 nm diameter were prepared from MLVs by extrusion
using a LiposoFast Extruder (Avestin, Inc., Ottawa, Ontario, Canada).
TheMLVswere freeze-thawedﬁve times using liquid nitrogen to ensure
solute equilibration between trapped and bulk solutions and then ex-
truded through polycarbonate ﬁlters (pore diameter of 100 nm)
mounted in the extruder ﬁttedwith Hamilton syringes (Hamilton Com-
pany, Reno, NV, USA). The samples were then subjected to 11 passes
through polycarbonate ﬁlters to give the ﬁnal LUV suspension. Samples
were incubated in dark for 12 h at room temperature (~23 °C) to equil-
ibrate before measuring ﬂuorescence. All experiments were done in
triplicate at room temperature.
2.5. Steady-state ﬂuorescence anisotropy measurements
LUVs were transferred to quartz cuvettes (of 1 cm path length) and
examined for changes in membrane ﬂuidity using a Hitachi F-7000 spec-
troﬂuorometer (Tokyo, Japan)ﬁttedwith aHitachi polarization accessory
(Hitachi High Technologies America, Inc., Schaumburg, IL, USA), which
was used to determine apparent rotational correlation time (ARCT)
values for DPH in each sample. Formonitoring DPH, the excitationwave-
lengthwas set at 358 nmand emissionwasmonitored at 430 nm. Excita-
tion and emission slits with bandpass of 1 and 5 nm were used for all
measurements. The excitation slit was set to the lowest possible aperture
to minimize photoisomerization of DPH during irradiation. Fluorescence
was measured with a 30 s interval between successive openings of the
excitation shutter to reverse any photoisomerization of DPH. Anisotropy
values were calculated from the equation:
r ¼ IVV−GIVH
IVV þ 2GIVH ð2Þ
where IVV and IVH are the measured ﬂuorescence intensities (after ap-
propriate background correction) with the excitation and emission
polarizers oriented vertically and horizontally, respectively. G is the
grating factor and is the ratio of the efﬁciencies of the detection system
for vertically and horizontally polarized light, and is equal to IHV/IHH.
2.6. Time-resolved ﬂuorescence measurements
Fluorescence lifetimes were calculated from time-resolved ﬂuores-
cence intensity decays using IBH 5000F NanoLED equipment (Horiba
JobinYvon, Edison, NJ) with DataStation software in the time-
correlated single photon counting (TCSPC) mode. A pulsed light-
emitting diode (LED) (NanoLED-16) was used as an excitation source.
This LED generates optical pulse at 337 nm with pulse duration 1.2 ns
and is run at 1 MHz repetition rate. The LED proﬁle (instrument re-
sponse function) was measured at the excitation wavelength using
Ludox (colloidal silica) as the scatterer. To optimize the signal-to-noise
ratio, 10,000 photon counts were collected in the peak channel. All ex-
periments were performed using emission slits with bandpass of
8 nm. The sample and the scatterer were alternated after every 10% ac-
quisition to ensure compensation for shape and timing drifts occurring
during the period of data collection. This arrangement also prevents
any prolonged exposure of the sample to the excitation beam, thereby
avoiding any possible photo damage of the ﬂuorophore. Data were
stored and analyzed using DAS 6.2 software (Horiba JobinYvon, Edison,
NJ). Fluorescence intensity decay curves so obtainedwere deconvoluted
with the instrument response function and analyzed as a sum of expo-
nential terms
F tð Þ ¼ Σi αi exp −t=τið Þ ð3Þ
where F(t) is the ﬂuorescence intensity at time t and αi is a pre-
exponential factor representing the fractional contribution to the
time-resolved decay of the component with a lifetime τi such that
Σiα= 1. The program also includes statistical and plotting subroutine
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chosen function was evaluated by the χ2 ratio, the weighted residuals,
and the autocorrelation function of the weighted residuals. A ﬁt was
considered acceptable when plots of the weighted residuals and the au-
tocorrelation function showed random deviation around zero with a
minimum χ2 value not N1.6. Intensity-averaged mean lifetimes bτ N for
biexponential decays of ﬂuorescence were calculated from the decay
times and pre-exponential factors using the following equation:
bτN ¼ α1τ
2
1 þ α2τ22
α1τ1 þ α2τ2 ð4Þ
In order to ensure that the anisotropy values measured for DPH
were not inﬂuenced by lifetime-induced artifacts, the apparent (aver-
age) rotational correlation times (ARCT) were calculated using Perrin's
equation:
τc ¼ bτNrr0−r ð5Þ
where r0 is the limiting anisotropy of DPH, r is the steady state anisotro-
py, and bτN is the mean ﬂuorescence lifetime [58].
2.7. Statistical analyses
Data were presented as mean ± SD (ﬂuorescence data) or SEM (x-
ray diffraction data) for (N) separate samples or treatment groups. Dif-
ferences between groups were analyzed using the two-tailed, Student's
t-test (for comparisons between only two groups) or ANOVA followed
by Dunnett or Student-Newman-Keuls multiple comparisons post-hoc
analysis (for comparisons between three or more groups). Alpha error
was set to 0.05 in this study.
3. Results
3.1. Comparative effects of EPA, DHA, and other test agents on the
disruption of pre-existing cholesterol domains in model membranes
To assesswhether EPA has a direct effect on domain formation inde-
pendent of its antioxidant properties, we evaluated the comparative
and disruptive effects of EPA, DHA, EPA+ DHA combination treatment,
as well as other polyunsaturated fatty acids (ALA, AA and DPA), lipid-
lowering agents (fenoﬁbrate, gemﬁbrozil, and niacin), and the positive
control, glycyrrhizin, on cholesterol domain structural organization in
model membranes prepared at 1.5:1 C/P—levels known to induce cho-
lesterol domain formation even in the absence of other perturbations
such as oxidative stress. Because cholesterol crystalline domains have
a consistent unit cell periodicity (d-space) value that is substantially
smaller than the typical plasma d-space value, the formation of these
domains can be evaluated and quantitated using small angle x-ray dif-
fraction [3,59,60]. As shown in Fig. 1, scattering data collected from
eachmembrane preparation yielded up to four phospholipid diffraction
orders having an average d-space value of 57.0 ± 0.6 Å (mean ± SD)
and consistent with an homogenously-distributed, lipid bilayer phase.
Each diffraction pattern also yielded an additional set of peaks with an
average d-space of 34Å and consistentwith a cholesterol crystalline do-
main phase. Differences in the relative intensity of these peaks indicate
material differences between the various treatments and are quantitat-
ed in Fig. 2.
Numeric reductions in cholesterol domain formation were observed
in all samples, with the exception of gemﬁbrozil, relative to vehicle-
treated controls (Fig. 2). EPA, glycyrrhizin, AA, and ALA had the most
pronounced effects, reducing cholesterol domain levels by 65.5%,
54.9%, 46.8%, and 45.2%, respectively (p b 0.05 for all pairwise compari-
sons with vehicle-treated controls). Lesser nonsigniﬁcant reductions,
and in some cases greater experimental variability, were observed forEPA + DHA combination treatment (29.6%), DPA (20.8%), DHA
(11.1%), niacin (35.0%), and fenoﬁbrate (1.4%) (p N 0.05 for all pairwise
comparisons with vehicle-treated controls). Gemﬁbrozil increased cho-
lesterol domain formation by a nonsigniﬁcant 10.9% as compared to
vehicle-treated controls (p N 0.05). The statistical signiﬁcance of EPA,
glycyrrhizin, AA, and ALA effectswere lost with ANOVAmodeling across
all treatment arms.
3.2. Dose-dependent effects of EPA on the disruption of pre-existing
cholesterol domains in model membranes
EPA was observed to reduce cholesterol domains levels to a much
greater extent than DHA, but was unable to exhibit that effect when
tested in equimolar combination with DHA (Fig. 2). These data sug-
gested that the cholesterol domain-lowering effects of EPA may be
dose-dependent. To test this hypothesis, we evaluated EPA in the
same model membrane system at additional (lower) doses. As shown
in Fig. 3, EPA reduced cholesterol domain levels in a dose-dependent
manner, beginning at 1:90 T/P mole ratio (15.0% reduction, n.s.), con-
tinuing through 1:60 T/P mole ratio (30.2% reduction, n.s.), and culmi-
nating in a 65.5% reduction (p= 0.0139) at the 1:30 T/P mole ratio.
3.3. Comparative and dose-dependent effects of EPA and DHA on
membrane ﬂuidity
EPA and DHA were ﬁrst tested in membranes prepared in the ab-
sence of cholesterol; however, these membranes were so highly disor-
dered that neither treatment was observed to have any substantive
effect on DPH ARCT as compared to controls (data not shown). To re-
solve this issue, we added cholesterol to the membrane preparations
at 50 mol%, which has been shown to signiﬁcantly increase membrane
order, as evidenced by a nearly 7-fold increase in ARCT measured for
DPH (from 2.85 to 19.35 ns) [58], and to predispose cholesterol crystal-
line domain formation [61]. When EPA and DHA were tested in mem-
branes prepared at 50 mol% cholesterol (Fig. 4), EPA was found to
have no signiﬁcant effect on DPH ARCT measured over 1–10 mol% as
compared to vehicle-treated controls; however, DHA signiﬁcantly re-
duced ARCT from 19.35 ns (control) to 15.56 ns (10 mol%) in a dose-
dependent manner, consistent with a signiﬁcant increase in membrane
isotropy or ﬂuidity. DHAwas also observed to have signiﬁcantly greater
effects onmembrane ﬂuidity as compared to EPA at both 5 and 10mol%
treatment levels.
3.4. Comparative effects of EPA and DHA on membrane width and
cholesterol domain formation in membranes prepared at cholesterol
levels that predispose domain formation
To better understand the structural parameters associated with the
ﬂuidity changes measured for EPA and DHA in the anisotropy study,
we also tested the comparative effects of EPA and DHA, each at
5 mol%, on changes in membrane width (d-space) and cholesterol do-
main formation inMLVs prepared at 50mol% cholesterol and examined
over a broad range of temperature conditions. As shown in Fig. 5, in-
creasing the temperature from 15 °C to 30 °C in vehicle-treated controls
reduced membrane bilayer width from 56.0 to 54.2 Å, consistent with a
thermally-induced phospholipid acyl chain disordering effect. A similar
pattern was observed in DHA-treated samples, withmembrane d-space
decreasing from 56.5 to 54.6 Å over the same temperature range, with
no effects that were signiﬁcantly different than those observed for
vehicle-treated controls. EPA had amuchmore pronounced effect on bi-
layer width; EPA signiﬁcantly increased membrane d-space at each
temperature condition (p b 0.05) as compared to controls. This effect
was also temperature-dependent, as membrane d-space decreased
from 59.8 to 57.2 Å in EPA samples over the experimental temperature
range. EPA also had a signiﬁcantly greater effect on membrane bilayer
width as compared to DHA at 20 °C (p b 0.05).
Fig. 1. Representative x-ray diffraction patterns collected from cholesterol-enrichedmodel membranes treated with vehicle (control), eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA), EPA+DHA combination treatment, fenoﬁbrate (Fenoﬁb), nicotinic acid (Niacin), gemﬁbrozil (Gemﬁb), glycyrrhizin (Glyc), arachidonic acid (AA), α-linolenic acid (ALA), or
docosapentaenoic acid (DPA). Membranes were reconstituted from palmitoyloleoylphosphatidylcholine (POPC) and cholesterol at a cholesterol-to-phospholipid (C/P) mole ratio of
1.5:1 and treated with each of the various agents to achieve a total drug-to-phospholipid (D/P) mole ratio of 1:30. In each panel, diffraction peaks highlighted in red correspond to a cho-
lesterol crystalline domain phase, which has a characteristic periodicity (d-space value) of 34Å; peaks labeled 1 through 4 correspond to the surroundingmembrane phospholipid bilayer
phase, which was observed to have an average periodicity of 57 Å.
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fects. As shown in Fig. 6, cholesterol domains were not observed in any
of the vehicle- or EPA-treated samples and were not evoked by broad
changes in temperature. In contrast, treatmentwithDHA induced the for-
mation of prominent cholesterol crystalline domains, which remained
stable over the entire experimental temperature range.
4. Discussion
We recently reported that EPA inhibits the formation of cholesterol
domains in membranes exposed to oxidative stress [47]. The current
data now show that EPA also inhibits the formation of cholesteroldomains, independent of mechanisms associated with oxidative stress,
in a dose-dependent manner, and under conditions of elevated choles-
terol, suggesting that EPA has a direct physicochemical effect on mem-
brane lipid organization under disease-like conditions. We ﬁrst
assessed whether EPA and other fatty acids or lipid-lowering agents
could inhibit cholesterol domain formation in model membranes de-
signed to form cholesterol domains spontaneously (i.e., membranes
prepared at a 1.5:1 C/P mole ratio). Compared to control, treatment
with EPA, glycyrrhizin, AA, and ALA resulted in the greatest inhibition
of cholesterol domain formation inmembranes prepared in this fashion.
Minor changes in cholesterol domain formationwere observedwith the
lipid-lowering agents, fenoﬁbrate, gemﬁbrozil, or niacin. The inhibitory
Fig. 2. Comparative effects of glycyrrhizin (Glyc), α-linolenic acid (ALA), arachidonic acid
(AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid
(DHA), fenoﬁbrate (Fenoﬁb), nicotinic acid (Niacin), and gemﬁbrozil (Gemﬁb) on mem-
brane cholesterol domain structural integrity. Values within parentheses after fatty acids
denote carbon length and number of unsaturated bonds; omega-3 (n-3) or -6 (n-6)
fatty acid classiﬁcation. Each agent was tested at D/P mole ratio of 1:30. Values are
mean ± SEM (N = 3–6). ANOVA: p= 0.0946, F = 1.864).
Fig. 4.Dose-dependent effects of EPA and DHA on the apparent rotational correlation time
(ARCT)measured for diphenylhexatriene (DPH) in POPCmembranes prepared at 50mol%
cholesterol. Values are mean ± SD (N= 3). *p b 0.05 versus control (vehicle) treatment;
†p b 0.05 versus cognate (equimolar) DHA treatment (Student-Newman-Keuls multiple
comparisons test; overall ANOVA: p= 0.0016; F = 6.778).
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mation were observed to numerically increase with increasing chain
length and degree of unsaturation fromALA to EPA and then to decrease
with further increases in chain length and unsaturation (from EPA to
DHA). As such, these agents could be ranked in order of their discrete ef-
fects on cholesterol domain formation as follows: ALA b AA b EPA N
DPA N DHA. This suggests that EPA may possess the optimal combina-
tion of chain length and degree of unsaturation for mitigating changes
in membrane structure, including cholesterol domain formation.
When considered togetherwith the dose-dependent, domain formation
inhibitory effects observed for EPA, these data suggest that EPAmay in-
terfere with the deleterious effects of cholesterol enrichment at the
membrane level, which could potentially translate, in vivo, to direct
atheroprotective beneﬁts.Fig. 3.Dose-dependent disruptive effects of EPA, versus vehicle and glycyrrhizin (Glyc), on
the structural integrity of pre-existingmembrane cholesterol domains.Modelmembranes
were prepared as binarymixtures of POPC and cholesterol at a C/P mole ratio of 1.5:1 and
treated with EPA at the D/P mole ratios indicated. Relative cholesterol peak intensity
values were derived by integrating the second order cholesterol domain peak and
normalizing to total phospholipid peak area associated with a given diffraction pattern.
Values are mean ± SEM (N = 3–6). *p b 0.05 versus vehicle (Student-Newman-Keuls
multiple comparisons analysis; overall ANOVA: p= 0.0085, F = 5.434).O3FAs are highlyﬂexible andhave been shown to increase the ﬂuidity
of endothelial cellmembranes [62]. DHA, for example, has been shown to
isomerize through each of its possible conﬁrmations within 50 ns after
being added to biological membranes [63]. High acyl chain ﬂexibility
and rapid conformational changes are thought to interfere with the
close association of O3FAs with cholesterol molecules, which have a
rigid steroid ring structure and are less ﬂexible in their membrane dispo-
sition [64]. In this study, we evaluated the comparative effects of EPA and
DHA onmembrane structure and ﬂuidity in model membranes prepared
at cholesterol levels that predispose domain formation (i.e., 1:1 C/P mole
ratio). As expected, modelmembranewidthwas observed to decrease as
a function of increasing temperature. Interestingly, similar temperature-
dependent decreases inmembranewidthwere observed in the presence
of EPA, but an increase in membrane width was observed at all tempera-
tures relative to vehicle-treated controls, andEPAdidnot altermembrane
ﬂuidity. In contrast, at all temperatures tested, DHA-treated membranes
showed no change in membrane width compared to controls, but DHA
did increasemembraneﬂuidity in a dose-dependentmanner. In addition,
DHA induced the formation of distinct cholesterol domains at all temper-
atures, while EPA, like vehicle-treated controls, demonstratedmembrane
lipid homogeneity. Thus, EPA andDHAwere distinguished in this study inFig. 5. Temperature-dependent effects of EPA and DHA onmembrane unit cell periodicity
(d-space) measured in POPC membranes prepared at 50 mol% cholesterol. Values are
mean ± S.D. (N = 3). *p= 0.0318 versus vehicle (at 15 °C); §p= 0.0259 versus vehicle
(at 20 °C); †p = 0.0491 versus DHA (at 20 °C);¶ p = 0.0207 versus vehicle (at 30 °C)
(unpaired, two-tailed Student's t-test).
Fig. 6. Representative x-ray diffraction patterns collected from cholesterol-enrichedmodelmembranes treatedwith vehicle (control), EPA, or DHA and examined at 15 °C, 20 °C, and 30 °C.
Membranes were reconstituted from POPC and cholesterol at 50mol% cholesterol and treatedwith each of the various agents at 5mol% (to match treatments used in corresponding lipid
dynamics experiments). Each sample wasmaintained at 74% relative humidity by exposing the samples to a saturated solution of L-(+) tartaric acid. Diffraction peaks associatedwith the
membrane phospholipid bilayer phase (labeled 1 through 4) were observed in all samples regardless of treatment or temperature condition. DHA, but not EPA or vehicle, induced the
formation of cholesterol domains, which are indicated by a distinct set of diffraction peaks (shown in red ﬁll) having a characteristic d-space value of 34 Å and shown to be stable over
a broad range of temperatures.
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itywhile DHA increased the formation of cholesterol crystalline domains,
had no overall effect on membrane width, and increased membrane ﬂu-
idity (Fig. 7). Theseﬁndings suggest that EPA allows cholesterol to remain
more evenly distributed within the membrane while DHA promotes the
simultaneous formation of highly-ordered, cholesterol-rich microdo-
mains and DHA-rich, lipid-disordered domains. This dual domain motif
appears to be balanced in regards to total membrane order, as demon-
strated by a lack of change inmembranewidth, and seems to be in agree-
ment with a model proposed by Shaikh et al. [32]. These ﬁndings are
consistent with previous studies showing that DHA has a greater effect
on endothelial membrane ﬂuidity relative to EPA and suggests that acyl
chain length or the number of double bonds differentially affects ﬂuidity
and the formation of membrane domains [62]. These results also suggest
that DPH may preferentially locate within the more-ﬂuid, DHA-rich do-
mains as opposed to themore-ordered, cholesterol-rich domains. Despite
experimental constraints, EPA prevented changes in cholesterol domain
formation and membrane ﬂuidity, suggesting an inherent ability to nor-
malize membrane structural features despite shifts in temperature or
cholesterol content.
The results reported herein showing that EPA confers stability to
membranes is consistent with some previous studies [62,65]; however,
as mentioned above, other studies have shown that EPA, like DHA, is
able to increase membrane ﬂuidity [66,67]. In addition, these data sug-
gest that DHA induces the formation of cholesterol domains, but previ-
ous studies have shown that treatment with DHA decreases membranecholesterol content [62]. These differences are likely explained by the
different experimental models employed in each study. Unlike in vivo
or cell culture (in vitro) experimental systems, the data presented in
this study were generated in a closed, controlled model system in
which cholesterol was restricted to the membrane alone; that is, there
were no internal or external cholesterol acceptors, as in natural or cell
culture systems, thatmight otherwise affectmembrane cholesterol con-
tent. As such, this model system allows for a direct assessment of the
structural effects of cholesterol, O3FAs, and other molecules, without
the need to control extraneous effects; however, an important next
step is to examine these effects in more advanced, cell culture or
in vivo, systems.
These data also suggest that EPA may support normal cellular func-
tion even in a state of increased cholesterol load, which could have im-
portant implications in disease conditions such as atherosclerosis. For
example, disruption of membrane structure and the formation of
cholesterol-rich domains may affect endothelial function, vascular
tone, cytokine expression, and immunity as well as recruitment and ac-
tivation of inﬂammatory cells [5,9]. By reducing the volume or number
of lipid rafts present in endothelial membranes, EPA may disengage
stress-induced signaling complexes in caveolae, thus reducing endothe-
lial dysfunction (e.g., increasing eNOS secretion) [68] and vascular in-
ﬂammation (e.g., inhibiting NLRP3 inﬂammasome activation) [69],
which may have clinically-signiﬁcant cardiovascular beneﬁts [9,
70–72]. Overall, by mitigating the formation of cholesterol-rich do-
mains, treatment with EPA may provide positive beneﬁts in a variety
Fig. 7. Schematic illustration of the proposed effects of EPA and DHA onmembrane structural and dynamic properties as determined in this study. EPA intercalates into the hydrocarbon
core region of the membrane lipid bilayer where it provides important antioxidant beneﬁts, as previously reported, but without inducing any signiﬁcant changes in membrane ﬂuidity,
bilayer width, and cholesterol distribution. In contrast, DHA increases membrane ﬂuidity, promotes the formation of discrete, cholesterol crystalline domains, and reduces the overall
width of the membrane bilayer. The distinct effects of DHA as measured in this study are attributed to its greater molecular length and reduced saturation level, which alters
membrane phospholipid packing constraints, effectively increasing molecular space in the hydrocarbon core, with subsequent effects on cholesterol redistribution and bilayer width.
Note: The precise locations of the molecules depicted in this schematic are not known and are only suggested as a means of broadly illustrating the disparate effects of EPA and DHA
on membrane lipid structural organization.
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and autoinﬂammatory disease.
The structural-functional differences observed for EPA andDHA in this
study suggest that both fatty acid chain length and the degree of
unsaturation are important determinants of activity in cellular mem-
branes. An important next step would be to test in vivo the comparative
effects of EPA and DHA, against other anti-hypertriglyceridemic medica-
tions, ideally in awell-controlled, outcomes-based clinical trial. A few ran-
domized, controlled clinical outcome studies with omega-3 fatty acids
have demonstrated signiﬁcant reductions in cardiovascular risk [17–30,
73] and coronary plaque regression [39]. Unfortunately, drawing an over-
all conclusion from the results of these studies is challenging because of
limitations in study design such as the use of different formulations of
EPA and DHA, subtherapeutic omega-3 dosing, potential underutilization
of statin therapy, and lack of statistical power. In an effort to conﬁrm
whether an EPA-only formulation can reduce cardiovascular risk,particularly in a broad patient population, a well-controlled cardiovascu-
lar outcomes study is underway. This study, known as the Reduction of
Cardiovascular Events with Eicosapentaenoic Acid Intervention Trial (RE-
DUCE-IT), is evaluating the ability of a high purity prescription EPA-only
formulation to reduce cardiovascular mortality and morbidity in a high-
risk patient population with persistently high TG levels in spite of statin
therapy [74].
5. Conclusion
The data presented in this report regarding model membranes sug-
gests that EPA may provide atheroprotection through its direct effects
on biological membranes. Conversely, these effects were not observed
in model membranes treated with DHA. While treatment with EPA sta-
bilized membranes in the presence of increasing temperature and cho-
lesterol levels, treatmentwithDHA induced the formation of cholesterol
3139R.P. Mason et al. / Biochimica et Biophysica Acta 1858 (2016) 3131–3140domains and altered membrane structure and ﬂuidity, suggesting that
EPA and DHA have very distinct membrane interaction effects. By re-
ducing the accumulation of cholesterol-rich domains in atherosclerotic
membranes, EPA may reduce inﬂammation and improve endothelial
function. Further evaluation of the differential effects of omega-3 fatty
acids on membrane physiology is warranted, and will be important to
clarify the potential beneﬁts of EPA relative to DHA in treating cardio-
vascular disease.
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